The company, which is domiciled on the British Virgin Islands and has a corporate office in Canada, creates much of its value by developing pre-proof of concept assets through proof of concept, after which big pharma is often interested in acquiring or licensing them.

Portage's access to a broad network of drug development professionals helps to ensure the optimum development pathway for each compound. The company has three major portfolio companies - Portage Pharmaceuticals, Biohaven Pharmaceuticals and Sentien Biotechnologies.